HK$6 million grant awarded to advance Asia-Pacific execution
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Nexsen Limited has announced the awarding of a significant grant to support its Asia-Pacific strategy. The grant will fund clinical validation and manufacturing scale-up for the company's StrepSure® diagnostic product. This initiative positions Hong Kong as a key hub for Nexsen's manufacturing and distribution efforts in the region. The funding will enable the company to initiate local clinical validation studies and establish manufacturing capabilities in Hong Kong.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Nexsen
- Nexsen accelerates global rollout for StrepSure
- FDA feedback derisks US approval pathway for StrepSure
- Half Yearly Report and Accounts
- Quarterly Report - Q2 FY26
- $500k govt grant expands GBS project to neonates
Later from Nexsen
- QMS milestone achieved
- Quarterly Report - Q3 FY26
- Nexsen and Universiti Malaya launch joint facility
- Nexsen secures first hospital partner in Asia
- $1.5m non-dilutive ARC funding for manufacturing
Follow Nexsen into a list and get an email when it puts out news.
Follow Nexsen